RESUMEN
The FRhL-2 cell line, a diploid line derived from the lung of a fetal rhesus monkey, was used to prepare a potent rabies vaccine by adapting the Kissling strain of rabies virus to FRhL-2 cells, growing the virus in quantity, inactivating the virus with beta-propiolactone, and concentrating the virus by adsorption to aluminum phosphate. High levels of antibody to rabies virus, induced by the vaccine in both guinea pigs and humans at 14 days after immunization, were determined to be IgG. Data from postexposure protocols with guinea pigs and simulated postexposure protocols in humans showed protection and antibody response even when rabies immune globulin was administered at the time of vaccination.
Asunto(s)
Anticuerpos Antivirales/biosíntesis , Vacunas Antirrábicas/inmunología , Virus de la Rabia/inmunología , Rabia/prevención & control , Animales , Línea Celular , Cobayas , Humanos , Inmunización Pasiva , Inmunización Secundaria , Inmunoglobulina G/biosíntesis , Inmunoglobulina M/biosíntesis , Pulmón , Macaca mulatta , Virus de la Rabia/crecimiento & desarrollo , Vacunación , Cultivo de VirusRESUMEN
Rhesus diploid-cell-strain rabies vaccine (RDRV) (adsorbed) is a new rabies vaccine intended for use in man. Sixty volunteers were given five doses of RDRV at 0, 3, 7, 14, and 28 days to simulate prophylactic treatment of persons exposed to a rabid animal. Thirty-five volunteers were given commercial high-titer rabies immune globulin, 20 IU/kg, before the first dose of RDRV, and 25 were given RDRV without prior rabies immune globulin. Antibody responses at 14, 28, and 42 days were comparable with those reported with human diploid rabies vaccine. Simulated postexposure prophylactic treatment with RDRV was associated with acceptable levels of local and constitutional symptoms.
Asunto(s)
Vacunas Antirrábicas/uso terapéutico , Rabia/prevención & control , Adsorción , Animales , Anticuerpos Antivirales/análisis , Ensayos Clínicos como Asunto , Femenino , Humanos , Inyecciones Intramusculares , Macaca mulatta , Masculino , Vacunas Antirrábicas/administración & dosificación , Virus de la Rabia/inmunologíaRESUMEN
To meet the need for a safe, efficacious, and low-cost rabies vaccination program, the Michigan Department of Public Health developed a new rabies vaccine: rhesus diploid rabies vaccine, adsorbed (RDRV). Initial clinical studies were conducted in 534 volunteers using preexposure protocols consisting of two injections of RDRV given 1, 2, or 4 weeks apart. This new rabies vaccine induced an excellent rabies virus antibody response two to three weeks after vaccination: antibody levels were superior to those reported after duck embryo rabies vaccine and were similar to those reported with human diploid rabies vaccine. In addition, vaccination with RDRV was associated with an acceptable level of local and constitutional symptoms.
Asunto(s)
Anticuerpos Antivirales/análisis , Vacunas Antirrábicas , Rabia/prevención & control , Vacunación , Adolescente , Adulto , Anciano , Animales , Línea Celular , Ensayos Clínicos como Asunto , Diploidia , Femenino , Humanos , Macaca mulatta/inmunología , Masculino , Persona de Mediana Edad , Rabia/inmunología , Vacunas Antirrábicas/normas , Virus de la Rabia/inmunología , Vacunación/métodosRESUMEN
While studying variations amony immunizing potentials of rabies vaccines, we were led to consider the possibility that the antigen in the vaccine derived from duck embryos may have been degraded by enzymes arising from host tissues. Such an enzyme, a neuraminidase, was found in duck embryo rabies vaccine through the application of a periodate-linked thiobarbituric acid assay. This acitvity could not be found in two other rabies vaccines derived from tissue cultures. We have thus concluded that there is a strong possibility that a modified antigen is present in duck embryo vaccine. In addition, the injection of this vaccine will introduce a neuraminidase which may produce localized effects in the tissues of the recipient.